# Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

> **NCT04068974** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Recurrent Platinum-resistant Ovarian Cancer

## Interventions

- **DRUG:** Camrelizumab (SHR-1210)
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT04068974
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-28
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2021-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04068974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04068974, "Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04068974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*